KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other Non-Current Assets (2016 - 2025)

Gsk (GSK) has 4 years of Other Non-Current Assets data on record, last reported at $2.0 billion in Q4 2023.

  • For Q4 2023, Other Non-Current Assets rose 40.38% year-over-year to $2.0 billion; the TTM value through Dec 2023 reached $2.0 billion, up 40.38%, while the annual FY2023 figure was $2.0 billion, 33.33% up from the prior year.
  • Other Non-Current Assets reached $2.0 billion in Q4 2023 per GSK's latest filing, up from $1.4 billion in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.3 billion in Q4 2021 and bottomed at $1.4 billion in Q4 2022.
  • Average Other Non-Current Assets over 3 years is $1.9 billion, with a median of $2.0 billion recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: plummeted 38.01% in 2022, then soared 40.38% in 2023.
  • A 3-year view of Other Non-Current Assets shows it stood at $2.3 billion in 2021, then tumbled by 38.01% to $1.4 billion in 2022, then skyrocketed by 40.38% to $2.0 billion in 2023.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $2.0 billion in Q4 2023, $1.4 billion in Q4 2022, and $2.3 billion in Q4 2021.